Chromosome 3p tumor-suppressor gene alterations in cervical carcinomas

被引:9
作者
Herzog, CR
Crist, KA
Sabourin, CLK
Kelloff, GJ
Boone, CW
Stoner, GD
You, M
机构
[1] Ohio State Univ, James Canc Ctr, Div Human Canc Genet, Med Res Facil 646, Columbus, OH 43210 USA
[2] Amer Hlth Fdn, Div Nutr Carcinogenesis, Valhalla, NY 10595 USA
[3] Med Coll Ohio, Toledo, OH 43699 USA
[4] NCI, Chemoprevent Branch, Bethesda, MD 20892 USA
关键词
3p; loss of heterozygosity; transforming growth factor-beta type II receptor; fragile histidine triad; cervical carcinoma;
D O I
10.1002/mc.1024
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Loss of heterozygosity (LOH) on chromosome 3p is a common event in cervical cancer and typically occurs in a dispersed pattern involving several loci. This implies that more than one resident tumor-suppressor gene is involved in the genesis of these tumors; however, specific targets remain to be identified. The region of 3p 14.2-pter encompasses a region of frequent loss and contains at least three tumor-suppressor genes: fragile histidine triad (FHIT), transforming growth factor-beta receptor II (T betaR-II), and Von Hippel-Lindau. To identify those loci within 3p 14.2-pter that are important in cervical cancer, invasive tumors were first subjected to high-density LOH analysis. With 25 microsatellite markers, LOH was detected in seven of 15 cervical carcinomas (47%). Losses always included markers mapping to 3p22, and markers at this location were exclusively lost in two tumors, implicating this as a site of a cervical tumor-suppressor gene. Because it is a known tumor-suppressor gene located at 3p22 and thus a potential target for inactivation in these tumors, the T betaR-II gene was subsequently screened for mutation and altered expression levels. Whereas no tumor-derived mutations were detected in any of the tumors, six of ten tumors showed T betaR-II transcript levels reduced by greater than or equal to 50% when compared with normal cervical epithelium. Nine of 15 (60%) tumors exhibited LOH at 3p22 or reduced expression of T betaR-II, suggesting that reduced T betaR-II levels contribute to cervical tumorigenesis. Two cases exhibited silent germline polymorphisms of T betaR-II: one corresponding to a C1167T transversion and the other to an A1266G transition. The FHIT gene, which is located at 3p 14.2, also frequently incurred LOH and abnormal transcription in these tumors. LOH of FHIT was observed in five of the 15 tumors analyzed. Neither mutations nor homozygous deletions of FHIT were detected in the tumors. However, aberrantly short transcripts of the FHIT gene were evident in six of nine (67%) tumors. Only one of these also displayed LOH, indicating that this gene was altered in at least 10 of 15 (67%) tumors. These results provide evidence that the inactivation of two known tumor-suppressor genes, T betaR-II and FHIT, on chromosome 3p is involved in cervical carcinogenesis. (C) 2001 Wiley-Liss, Inc.
引用
收藏
页码:159 / 168
页数:10
相关论文
共 51 条
[11]   Muir-Torre-like syndrome in Fhit-deficient mice [J].
Fong, LYY ;
Fidanza, V ;
Zanesi, N ;
Lock, LF ;
Siracusa, LD ;
Mancini, R ;
Siprashvili, Z ;
Ottey, M ;
Martin, SE ;
Druck, T ;
McCue, PA ;
Croce, CM ;
Huebner, K .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2000, 97 (09) :4742-4747
[12]  
FYNAN TM, 1993, CRIT REV ONCOGENESIS, V4, P493
[13]  
Gemma A, 1997, CANCER RES, V57, P1435
[14]   TRANSLOCATION T(3-8)(P14.2-Q24.1) IN RENAL-CELL CARCINOMA AFFECTS EXPRESSION OF THE COMMON FRAGILE SITE AT 3P14(FRA3B) IN LYMPHOCYTES [J].
GLOVER, TW ;
COYLEMORRIS, JF ;
LI, FP ;
BROWN, RS ;
BERGER, CS ;
GEMMILL, RM ;
HECHT, F .
CANCER GENETICS AND CYTOGENETICS, 1988, 31 (01) :69-73
[15]  
Greenspan DL, 1997, CANCER RES, V57, P4692
[16]   DPC4, a candidate tumor suppressor gene at human chromosome 18q21.1 [J].
Hahn, SA ;
Schutte, M ;
Hoque, ATMS ;
Moskaluk, CA ;
daCosta, LT ;
Rozenblum, E ;
Weinstein, CL ;
Fischer, A ;
Yeo, CJ ;
Hruban, RH ;
Kern, SE .
SCIENCE, 1996, 271 (5247) :350-353
[17]  
Hendricks DT, 1997, CANCER RES, V57, P2112
[18]   Inactivation of the transforming growth factor β type II receptor in human small cell lung cancer cell lines [J].
Hougaard, S ;
Norgaard, P ;
Abrahamsen, N ;
Moses, HL ;
Spang-Thomsen, M ;
Poulsen, HS .
BRITISH JOURNAL OF CANCER, 1999, 79 (7-8) :1005-1011
[19]   The role of the FHIT/FRA3B locus in cancer [J].
Huebner, K ;
Garrison, PN ;
Barnes, LD ;
Croce, CM .
ANNUAL REVIEW OF GENETICS, 1998, 32 :7-31
[20]  
Ji L, 1999, CANCER RES, V59, P3333